--- title: "Popular pre-market trades in the US stock market: Delixy pre-market up 22.64%; Brand Engagement Network pre-market down 21.63%" type: "News" locale: "en" url: "https://longbridge.com/en/news/278353267.md" description: "Delixy pre-market up 22.64%; Brand Engagement Network pre-market down 21.63%; Hims & Hers Health pre-market up 43.20%; EON Resources pre-market up 39.84%; uniQure pre-market up 30.76%" datetime: "2026-03-09T08:12:42.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/278353267.md) - [en](https://longbridge.com/en/news/278353267.md) - [zh-HK](https://longbridge.com/zh-HK/news/278353267.md) generator: "portal-rs" --- # Popular pre-market trades in the US stock market: Delixy pre-market up 22.64%; Brand Engagement Network pre-market down 21.63% **Popular Pre-Market Trades in US Stocks** Delixy, up 22.64% in pre-market trading, has no significant news recently. The trading is active with clear capital flow, and considering the sector and industry trends, the stock shows significant volatility, with specific reasons needing further observation. Brand Engagement Network, down 21.63% in pre-market trading, has no significant news recently. The trading is active with clear capital flow, and considering the sector and industry trends, the stock shows significant volatility, with specific reasons needing further observation. **Top Gainers in Pre-Market Trading in US Stocks** Hims & Hers Health is up 43.20% in pre-market trading. Based on recent key news: 1. On March 7, Hims & Hers Health reached a cooperation agreement with Novo Nordisk, where Novo Nordisk will sell weight loss drugs on the Hims platform, ending previous legal disputes. This news drove Hims' stock price up over 35% in after-hours trading. Source: Gelonghui 2. On March 9, Hims & Hers Health reached a settlement with Novo Nordisk regarding patent infringement issues, planning to jointly sell obesity drugs. The restart of this partnership led to a nearly 20% increase in Hims' stock price in after-hours trading. Source: MoneyDJ News 3. On March 6, JP Morgan reduced its stake in Hims & Hers Health from 8.1% to 1.7%, attracting market attention. Source: U.S. Securities and Exchange Commission documents. The trend of collaboration in the telemedicine industry is strengthening, with high market attention. EON Resources is up 39.84% in pre-market trading. Based on recent news: 1. On March 9, EON Resources announced the successful digitization of brain consciousness in mouse experiments. This breakthrough has attracted significant market attention, and investors are confident in the company's future potential in the field of bio-digitalization, driving the stock price up significantly. 2. On March 8, EON Resources released a video showcasing its technology, demonstrating the behavior output of a real biological digital brain in a simulated world. This video further enhanced market recognition of the company's technological strength, leading to continued stock price increases. 3. On March 7, EON Resources' chief scientist shared the latest research findings on multi-behavior brain uploading on social media. This news sparked widespread discussion and attention, further driving the stock price up. The biotechnology industry has performed strongly recently, with investor sentiment high. uniQure is up 30.76% in pre-market trading. Based on recent key news: 1. On March 7, after the announcement that Prasad, head of the FDA's vaccine and biologics division, will leave at the end of April, uniQure's stock price rose 61% in after-hours trading. Prasad's division has recently been in discussions with uniQure regarding its Huntington's disease gene therapy AMT-130. This news has sparked optimistic sentiment in the market regarding the therapy's approval prospects, driving the stock price up 2. On March 6, FDA senior officials criticized uniQure's trial design for its Huntington's disease gene therapy during a conference call, demanding a new placebo-controlled trial. Nevertheless, uniQure's stock price rose over 10% that day, indicating market confidence in its therapy. 3. On March 5, uniQure's Huntington's disease gene therapy was deemed unsuccessful by FDA officials in a randomized trial, leading to market doubts about its prospects. However, the stock price still rose 13% that day, reflecting investors' expectations for the company's future development. The gene therapy industry has seen significant fluctuations recently, and investors should exercise caution ### Related Stocks - [DLXY.US](https://longbridge.com/en/quote/DLXY.US.md) - [BNAI.US](https://longbridge.com/en/quote/BNAI.US.md) ## Related News & Research - [Brand Engagement Network forms 50/50 INTERVENT Health AI joint venture with INTERVENT International](https://longbridge.com/en/news/295976194.md) - [Ultragenyx Wins FDA Approval for GENGLYCOS, Its First Gene Therapy](https://longbridge.com/en/news/296478943.md) - [PTC Therapeutics Targets Fabry Gene Therapy in $111M Bankruptcy Auction Deal](https://longbridge.com/en/news/296027001.md) - [Tenaya Therapeutics Eyes Q4 Updates for Cardiac Gene Therapies, TN-301](https://longbridge.com/en/news/296321067.md) - [Biomarin To Acquire Alesta Therapeutics To Gain Ale1, A Potential First Oral Therapy For Hypophosphatasia](https://longbridge.com/en/news/296228796.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**